A5089164502- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer and Skin Lesions
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Molecular Biology Techniques and Applications
- Cancer Cells and Metastasis
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer, Hypoxia, and Metabolism
- Gene expression and cancer classification
- Neuroendocrine regulation and behavior
- Global Cancer Incidence and Screening
- Cancer Diagnosis and Treatment
- Breast Implant and Reconstruction
- Lung Cancer Research Studies
University of Turin
2016-2025
Candiolo Cancer Institute
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2024
Società Italiana di Cardiologia
2023
University of Rome Tor Vergata
2023
Fondazione Piemontese per la Ricerca sul Cancro Onlus
2013-2021
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2018
University of Verona
2006-2018
Vita-Salute San Raffaele University
2018
Dana-Farber Cancer Institute
2018
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification novel biomarkers better personalized medicine. We produced large xenograft cohorts 85 patient-derived, genetically characterized samples ("xenopatients") to discover determinants therapeutic response and new oncoprotein targets. Serially passaged tumors retained morphologic genomic features their...
The classification of breast tumours continues to evolve, with the integration new knowledge from research rapidly being translated into clinical practice. Major changes are shown in Table 1. In this volume World Health Organization (WHO) series’ fifth edition, which is an update fourth-edition published 2012,1 descriptions follow familiar systematic approach previous volumes, content now organised sequence benign epithelial proliferations and precursors, through neoplasms, in-situ invasive...
Although Ki67 index suffers from poor reproducibility, it is one of the most important prognostic markers used by oncologists to select treatment estrogen receptor (ER) positive breast cancer patients. In this study, we aim establish optimal cut-offs for stratifying patient prognosis and create a comprehensive clinical applications. A mono-institutional cohort 1.577 human epidermal growth factor 2 negative/ER+ patients having complete clinical, histological, follow-up data was collected. The...
Abstract Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but emergence resistance mutations restricts their efficacy. We previously showed that , BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during blockade, decline upon therapy withdrawal. hypothesized monitoring blood could rationally guide subsequent with anti-EGFR antibodies. report here results...
Abstract Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the research communities. We evaluated sources of variability sTIL assessment pathologists three previous ring studies. identify common challenges evaluate impact...
This article is an update of the requirements a specialist breast centre, produced by EUSOMA and endorsed ECCO as part Essential Requirements for Quality Cancer Care (ERQCC) programme, ESMO.To meet aspirations comprehensive cancer control, healthcare organisations must consider in this article, paying particular attention to multidisciplinarity patient-centred pathways from diagnosis, treatment, survivorship.•The centrepiece section, comprising definitions; multidisciplinary structure;...
Triple-negative breast cancer (TNBC) is considered aggressive, and therefore, virtually all young patients with TNBC receive (neo)adjuvant chemotherapy. Increased stromal tumor-infiltrating lymphocytes (sTILs) have been associated a favorable prognosis in TNBC. However, whether this association holds for who are node-negative (N0), (< 40 years), chemotherapy-naïve, thus can be used chemotherapy de-escalation strategies, unknown.We selected N0 diagnosed between 1989 2000 from Dutch...
The family of GH secretagogues (GHS) includes synthetic peptidyl (hexarelin) and nonpeptidyl (MK-0677) molecules possessing specific receptors in the pituitary central nervous system as well peripheral tissues, including heart some endocrine organs. A gastric-derived peptide, named ghrelin, has recently been proposed natural ligand GHS (GHS-Rs). presence GHS-Rs now investigated nontumoral neoplastic human breast tissue using a radioiodinated ([125I]-Tyr-Ala-hexarelin) ligand. Specific...
Abstract Approximately 8% of breast cancers show increased copy numbers chromosome 17 centromere (CEP17) by fluorescence in situ hybridization (FISH) (ie average CEP17 >3.0 per nucleus). Currently, this pattern is believed to represent polysomy 17. HER2 ‐amplified have been shown harbour complex patterns genetic aberrations 17, particular involving its long arm. We hypothesized that aberrant FISH assays may not necessarily true polysomy. Eighteen randomly selected polysomic cases and a...
Mutations in genes encoding proteins involved RNA splicing have been found to occur at relatively high frequencies several tumour types including myelodysplastic syndromes, chronic lymphocytic leukaemia, uveal melanoma, and pancreatic cancer, lower breast cancer. To investigate whether dysfunction is implicated the pathogenesis of we performed a re-analysis published exome whole genome sequencing data. This analysis revealed that mutations spliceosomal component occurred 5.6% unselected...
Invasive micropapillary carcinoma (IMPC) of the breast is a distinct and aggressive variant luminal type B cancer that does not respond to neoadjuvant chemotherapy. It characterized by small pseudopapillary clusters cells with inverted cell polarity. To investigate whether hypoxia-inducible factor-1 (HIF-1) activation may be related drug resistance described in this tumor, we used MCF7 cultured as 3-D spheroids, which morphologically simulate IMPC clusters. HIF-1 was measured EMSA ELISA...
Abstract Pure invasive micropapillary carcinoma (MPC) is a special histological type that accounts for 0.7–3% of all breast cancers. MPC has distinctive growth pattern and more aggressive clinical behaviour than ductal carcinomas no (IDC‐NSTs). To define the molecular characteristics MPCs, we profiled series 12 MPCs 24 grade oestrogen receptor (ER)‐matched IDC‐NSTs using high‐resolution microarray comparative genomic hybridization (aCGH). In addition, generated tissue containing performed...
BackgroundGene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of stromal signatures remains limited.Patients and methodsHere, we applied computational method CIBERSORT to generate 1028-gene matrix incorporating 17 immune cytotypes. Then, carried out deconvolution on publicly available GEP data 482 untreated DLBCLs reveal associations between clinical outcomes proportions...